SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | n/a |
| Book Value / Share | n/a |
| Price / Book | n/a |
| NCAV ($M) | 0.00 |
| NCAV / Share | n/a |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | n/a |
| Current Ratio | n/a |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | n/a |
| Assets | n/a |
| Liabilities | n/a |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | n/a |
| Operating Income | n/a |
| Net Income | n/a |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | n/a |
| Cash from Investing | n/a |
| Cash from Financing | n/a |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Tang Capital Partners Lp | 100.00 | -100.00 | |
| 13G/A | Frazier Life Sciences Public Fund, L.P. | 0.00 | -100.00 | |
| 13D/A | Orbimed Advisors Llc | 40.10 | 0.00 | |
| 13D/A | Foresite Capital Fund V, L.P. | 12.40 | 0.00 | |
| 13G/A | Fmr Llc | 0.00 | -99.95 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Similar Companies | |
|---|---|
| ABCL – AbCellera Biologics Inc. | ABOS – Acumen Pharmaceuticals, Inc. |
| ABUS – Arbutus Biopharma Corporation | ACAD – ACADIA Pharmaceuticals Inc. |
| ACLX – Arcellx, Inc. |
Financial data and stock pages provided by
Fintel.io